α-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium

Allison F O'Neill, Caihong Xia, Mark D Krailo, Furqan Shaikh, Farzana D Pashankar, Deborah F Billmire, Thomas A Olson, Jim F Amatruda, Doojduen Villaluna, Li Huang, Marcio Malogolowkin, Carlos Rodriguez-Galindo, A Lindsay Frazier, Allison F O'Neill, Caihong Xia, Mark D Krailo, Furqan Shaikh, Farzana D Pashankar, Deborah F Billmire, Thomas A Olson, Jim F Amatruda, Doojduen Villaluna, Li Huang, Marcio Malogolowkin, Carlos Rodriguez-Galindo, A Lindsay Frazier

Abstract

Background: There are several studies describing the correlation between unsatisfactory tumor marker decline and a poor prognosis for adult patients treated for germ cell tumors. In pediatric patients, the data are limited. Therefore, this study retrospectively analyzed data from Children's Oncology Group (COG) protocol AGCT0132 to determine whether a relationship exists between α-fetoprotein (AFP) decline and outcome.

Methods: One hundred thirty-one patients with germ cell tumors who were enrolled in COG protocol AGCT0132 were eligible for this analysis of AFP decline. The serum AFP half-life was calculated from levels collected postoperatively as a baseline and after the start of chemotherapy. AFP decline was defined as automatically satisfactory (AFP normalized within the first 2 AFP measures after the start of chemotherapy), calculated satisfactory (AFP half-life ≤7 days after the start of chemotherapy), and unsatisfactory.

Results: The 3-year cumulative incidence of relapse was 11% (95% confidence interval [CI], 6.0%-18%) for patients with a satisfactory decline and 38% (95% CI, 13%-64%) for patients with an unsatisfactory decline (P = .006). In stratified analyses, this effect was limited to patients who were 11 years of age or older and had standard risk 2 (SR2) disease (P = .004 and P = .007, respectively). Three-year overall survival (OS) for patients with a satisfactory decline versus an unsatisfactory decline was not statistically significant.

Conclusions: This study is the first to show an association between AFP decline and the cumulative incidence of relapse in pediatric patients treated for germ cell tumors. Recognition of patients at high risk for relapse may allow for early intensification of therapy, which could affect future clinical trial design.

Trial registration: ClinicalTrials.gov NCT00053352.

Keywords: germ cell; prognosis; α-fetoprotein (AFP).

© 2019 American Cancer Society.

References

    1. Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Institutes of Health; 1999. NIH publication 99-4649.
    1. Poynter JN, Amatruda JF, Ross JA. Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006. Cancer. 2010;116:4882-4891. doi:10.1002/cncr.25454
    1. Kaatsch P, Hafner C, Calaminus G, Blettner M, Tulla M. Pediatric germ cell tumors from 1987 to 2011: incidence rates, time trends, and survival. Pediatrics. 2015;135:e136-e143. doi:10.1542/peds.2014-1989
    1. Frazier AL, Hale JP, Rodriguez-Galindo C, et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol. 2015;33:195-201. doi:10.1200/JCO.2014.58.3369
    1. Shaikh F, Murray MJ, Amatruda JF, et al. Paediatric extracranial germ-cell tumours. Lancet Oncol. 2016;17:e149-e162. doi:10.1016/S1470-2045(15)00545-8
    1. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413-2418. doi:10.1200/JCO.2000.18.12.2413
    1. Feldman DR, Huddart R, Hall E, Beyer J, Powles T. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER trial. J Cancer. 2011;2:374-377.
    1. Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ. Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res. 1990;50:5904-5910.
    1. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol. 2001;19:2534-2541. doi:10.1200/JCO.2001.19.9.2534
    1. Murphy BA, Motzer RJ, Mazumdar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer. 1994;73:2520-2526.
    1. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22:3868-3876. doi:10.1200/JCO.2004.04.008
    1. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247-256. doi:10.1200/JCO.2005.05.4528
    1. Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15:1442-1450. doi:10.1016/S1470-2045(14)70490-5
    1. Fresneau B, Orbach D, Faure-Conter C, et al. Is alpha-fetoprotein decline a prognostic factor of childhood non-seminomatous germ cell tumours? Results of the French TGM95 study. Eur J Cancer. 2018;95:11-19. doi:10.1016/j.ejca.2018.02.029
    1. Shaikh F, Cullen JW, Olson TA, et al. Reduced and compressed cisplatin-based chemotherapy in children and adolescents with intermediate-risk extracranial malignant germ cell tumors: a report from the Children's Oncology Group. J Clin Oncol. 2017;35:1203-1210. doi:10.1200/JCO.2016.67.6544
    1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594-603. doi:10.1200/JCO.1997.15.2.594
    1. Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE. Marker half-life analysis as a prognostic tool in testicular cancer. J Urol. 1982;128:708-711.
    1. Blohm ME, Vesterling-Horner D, Calaminus G, Gobel U. Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol. 1998;15:135-142.
    1. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
    1. Geller NL, Bosl GJ, Chan EY. Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors. Cancer. 1989;63:440-445.
    1. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988;6:1231-1238. doi:10.1200/JCO.1988.6.8.1231
    1. Bosl GJ, Geller NL, Chan EY. Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors. Cancer Res. 1988;48:3524-3527.
    1. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7:387-391. doi:10.1200/JCO.1989.7.3.387

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться